Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Prostaglandin F-induced Prostate Transmembrane Protein, Androgen Induced 1 mediates ovarian cancer progression increasing epithelial plasticity.

Jiménez-Segovia A, Mota A, Rojo-Sebastián A, Barrocal B, Rynne-Vidal A, García-Bermejo ML, Gómez-Bris R, Hawinkels LJAC, Sandoval P, Garcia-Escudero R, López-Cabrera M, Moreno-Bueno G, Fresno M, Stamatakis K.

Neoplasia. 2019 Nov 14;21(11):1073-1084. doi: 10.1016/j.neo.2019.10.001. [Epub ahead of print]

PMID:
31734628
2.

Exosome-mimetic nanoplatforms for targeted cancer drug delivery.

Vázquez-Ríos AJ, Molina-Crespo Á, Bouzo BL, López-López R, Moreno-Bueno G, de la Fuente M.

J Nanobiotechnology. 2019 Jul 18;17(1):85. doi: 10.1186/s12951-019-0517-8.

3.

MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.

Majem B, Parrilla A, Jiménez C, Suárez-Cabrera L, Barber M, Marín A, Castellví J, Tamayo G, Moreno-Bueno G, Ponce J, Matias-Guiu X, Alameda F, Romero I, Sánchez JL, Pérez-Benavente A, Moran S, Esteller M, Reventós J, Rigau M, Gil-Moreno A, Segura MF, Santamaría A.

Oncogene. 2019 Aug;38(32):6035-6050. doi: 10.1038/s41388-019-0860-0. Epub 2019 Jul 5.

PMID:
31278368
4.

Contribution of Epithelial Plasticity to Therapy Resistance.

Santamaría PG, Moreno-Bueno G, Cano A.

J Clin Med. 2019 May 14;8(5). pii: E676. doi: 10.3390/jcm8050676. Review.

5.

Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness.

Molina-Crespo Á, Cadete A, Sarrio D, Gámez-Chiachio M, Martinez L, Chao K, Olivera A, Gonella A, Díaz E, Palacios J, Dhal PK, Besev M, Rodríguez-Serrano M, García Bermejo ML, Triviño JC, Cano A, García-Fuentes M, Herzberg O, Torres D, Alonso MJ, Moreno-Bueno G.

Clin Cancer Res. 2019 Aug 1;25(15):4846-4858. doi: 10.1158/1078-0432.CCR-18-2381. Epub 2019 May 7.

PMID:
31064780
6.

Updating the role of obesity and cholesterol in breast cancer.

Garcia-Estevez L, Moreno-Bueno G.

Breast Cancer Res. 2019 Mar 1;21(1):35. doi: 10.1186/s13058-019-1124-1. Review.

7.

Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer.

Blasco-Benito S, Moreno E, Seijo-Vila M, Tundidor I, Andradas C, Caffarel MM, Caro-Villalobos M, Urigüen L, Diez-Alarcia R, Moreno-Bueno G, Hernández L, Manso L, Homar-Ruano P, McCormick PJ, Bibic L, Bernadó-Morales C, Arribas J, Canals M, Casadó V, Canela EI, Guzmán M, Pérez-Gómez E, Sánchez C.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3863-3872. doi: 10.1073/pnas.1815034116. Epub 2019 Feb 7. Erratum in: Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6505.

8.

A role for the Tgf-β/Bmp co-receptor Endoglin in the molecular oscillator that regulates the hair follicle cycle.

Calvo-Sánchez MI, Fernández-Martos S, Carrasco E, Moreno-Bueno G, Bernabéu C, Quintanilla M, Espada J.

J Mol Cell Biol. 2019 Jan 1;11(1):39-52. doi: 10.1093/jmcb/mjy051.

9.

The Ras-related gene ERAS is involved in human and murine breast cancer.

Suárez-Cabrera C, de la Peña B, González LL, Page A, Martínez-Fernández M, Casanova ML, Paramio JM, Rojo-Sebastián A, Moreno-Bueno G, Maroto A, Ramírez Á, Navarro M.

Sci Rep. 2018 Aug 29;8(1):13038. doi: 10.1038/s41598-018-31326-4.

10.

In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines.

Rincón-Fernández D, Culler MD, Tsomaia N, Moreno-Bueno G, Luque RM, Gahete MD, Castaño JP.

Carcinogenesis. 2018 Mar 8;39(3):447-457. doi: 10.1093/carcin/bgx146.

PMID:
29272342
11.

A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination.

Figueras A, Alsina-Sanchís E, Lahiguera Á, Abreu M, Muinelo-Romay L, Moreno-Bueno G, Casanovas O, Graupera M, Matias-Guiu X, Vidal A, Villanueva A, Viñals F.

Mol Cancer Ther. 2018 Feb;17(2):532-543. doi: 10.1158/1535-7163.MCT-17-0643. Epub 2017 Nov 16.

12.

Prostaglandin E2 Leads to the Acquisition of DNMT3A-Dependent Tolerogenic Functions in Human Myeloid-Derived Suppressor Cells.

Rodríguez-Ubreva J, Català-Moll F, Obermajer N, Álvarez-Errico D, Ramirez RN, Company C, Vento-Tormo R, Moreno-Bueno G, Edwards RP, Mortazavi A, Kalinski P, Ballestar E.

Cell Rep. 2017 Oct 3;21(1):154-167. doi: 10.1016/j.celrep.2017.09.018.

13.

Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.

Salvador F, Martin A, López-Menéndez C, Moreno-Bueno G, Santos V, Vázquez-Naharro A, Santamaria PG, Morales S, Dubus PR, Muinelo-Romay L, López-López R, Tung JC, Weaver VM, Portillo F, Cano A.

Cancer Res. 2017 Nov 1;77(21):5846-5859. doi: 10.1158/0008-5472.CAN-16-3152. Epub 2017 Jul 18.

14.

Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences.

Gatius S, Cuevas D, Fernández C, Roman-Canal B, Adamoli V, Piulats JM, Eritja N, Martin-Satue M, Moreno-Bueno G, Matias-Guiu X.

Pathobiology. 2018;85(1-2):35-40. doi: 10.1159/000475529. Epub 2017 Jun 15.

15.

EMT: Present and future in clinical oncology.

Santamaria PG, Moreno-Bueno G, Portillo F, Cano A.

Mol Oncol. 2017 Jul;11(7):718-738. doi: 10.1002/1878-0261.12091. Epub 2017 Jun 27. Review.

16.

LOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway.

Cuevas EP, Eraso P, Mazón MJ, Santos V, Moreno-Bueno G, Cano A, Portillo F.

Sci Rep. 2017 Mar 23;7:44988. doi: 10.1038/srep44988.

17.

Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.

García-Sanz P, Triviño JC, Mota A, Pérez López M, Colás E, Rojo-Sebastián A, García Á, Gatius S, Ruiz M, Prat J, López-López R, Abal M, Gil-Moreno A, Reventós J, Matias-Guiu X, Moreno-Bueno G.

Int J Cancer. 2017 Apr 1;140(7):1551-1563. doi: 10.1002/ijc.30573. Epub 2017 Feb 2.

18.

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA.

Oncogene. 2017 May 11;36(19):2737-2749. doi: 10.1038/onc.2016.427. Epub 2016 Dec 19.

19.

Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.

Peinado H, Alecˇković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar CM, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D.

Nat Med. 2016 Dec 6;22(12):1502. doi: 10.1038/nm1216-1502b. No abstract available.

PMID:
27923027
20.

Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer.

Devis L, Moiola CP, Masia N, Martinez-Garcia E, Santacana M, Stirbat TV, Brochard-Wyart F, García Á, Alameda F, Cabrera S, Palacios J, Moreno-Bueno G, Abal M, Thomas W, Dufour S, Matias-Guiu X, Santamaria A, Reventos J, Gil-Moreno A, Colas E.

J Pathol. 2017 Mar;241(4):475-487. doi: 10.1002/path.4851. Epub 2017 Jan 23.

PMID:
27873306
21.

Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers.

Mota A, Colás E, García-Sanz P, Campoy I, Rojo-Sebastián A, Gatius S, García Á, Chiva L, Alonso S, Gil-Moreno A, González-Tallada X, Díaz-Feijoo B, Vidal A, Ziober-Malinowska P, Bobiński M, López-López R, Abal M, Reventós J, Matias-Guiu X, Moreno-Bueno G.

Mod Pathol. 2017 Jan;30(1):134-145. doi: 10.1038/modpathol.2016.143. Epub 2016 Sep 2.

22.

Cancer network activity associated with therapeutic response and synergism.

Serra-Musach J, Mateo F, Capdevila-Busquets E, de Garibay GR, Zhang X, Guha R, Thomas CJ, Grueso J, Villanueva A, Jaeger S, Heyn H, Vizoso M, Pérez H, Cordero A, Gonzalez-Suarez E, Esteller M, Moreno-Bueno G, Tjärnberg A, Lázaro C, Serra V, Arribas J, Benson M, Gustafsson M, Ferrer M, Aloy P, Pujana MÀ.

Genome Med. 2016 Aug 24;8(1):88. doi: 10.1186/s13073-016-0340-x.

23.

The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.

Gahete MD, Rincón-Fernández D, Durán-Prado M, Hergueta-Redondo M, Ibáñez-Costa A, Rojo-Sebastián A, Gracia-Navarro F, Culler MD, Casanovas O, Moreno-Bueno G, Luque RM, Castaño JP.

Oncotarget. 2016 Sep 13;7(37):60110-60122. doi: 10.18632/oncotarget.11076.

24.

Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.

Hellner K, Miranda F, Fotso Chedom D, Herrero-Gonzalez S, Hayden DM, Tearle R, Artibani M, KaramiNejadRanjbar M, Williams R, Gaitskell K, Elorbany S, Xu R, Laios A, Buiga P, Ahmed K, Dhar S, Zhang RY, Campo L, Myers KA, Lozano M, Ruiz-Miró M, Gatius S, Mota A, Moreno-Bueno G, Matias-Guiu X, Benítez J, Witty L, McVean G, Leedham S, Tomlinson I, Drmanac R, Cazier JB, Klein R, Dunne K, Bast RC Jr, Kennedy SH, Hassan B, Lise S, Garcia MJ, Peters BA, Yau C, Sauka-Spengler T, Ahmed AA.

EBioMedicine. 2016 Aug;10:137-49. doi: 10.1016/j.ebiom.2016.06.048. Epub 2016 Jul 2.

25.

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.

Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez Á, Castilla MÁ, González-Martin A, Pernas S, Cano A, Cortes J, Nuciforo PG, Peg V, Palacios J, Pujana MÁ, Arribas J, Moreno-Bueno G.

Oncotarget. 2016 Aug 30;7(35):56295-56308. doi: 10.18632/oncotarget.10787.

26.

Biological Effects of Temsirolimus on the mTOR Pathway in Endometrial Carcinoma: A Pharmacodynamic Phase II Study.

Santacana M, Coronado P, Matias-Guiu X, Romero I, Casado A, Gil-Moreno A, Dosil MA, Mota A, Moreno-Bueno G, Dolcet X, Llombart-Cussac A, Poveda A.

Int J Gynecol Cancer. 2016 Jun 2. [Epub ahead of print]

PMID:
27258723
27.

Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.

Mota A, Triviño JC, Rojo-Sebastian A, Martínez-Ramírez Á, Chiva L, González-Martín A, Garcia JF, Garcia-Sanz P, Moreno-Bueno G.

BMC Cancer. 2015 Nov 30;15:940. doi: 10.1186/s12885-015-1952-z.

28.

Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells.

Castellana B, Aasen T, Moreno-Bueno G, Dunn SE, Ramón y Cajal S.

Oncotarget. 2015 Nov 10;6(35):38239-56. doi: 10.18632/oncotarget.5664.

29.

The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes.

Adrados I, Larrasa-Alonso J, Galarreta A, López-Antona I, Menéndez C, Abad M, Gil J, Moreno-Bueno G, Palmero I.

Oncogene. 2016 Jul 7;35(27):3485-94. doi: 10.1038/onc.2015.408. Epub 2015 Oct 26.

30.

A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer.

Romero-Pérez L, Garcia-Sanz P, Mota A, Leskelä S, Hergueta-Redondo M, Díaz-Martín J, López-García MA, Castilla MA, Martínez-Ramírez A, Soslow RA, Matias-Guiu X, Moreno-Bueno G, Palacios J.

Mod Pathol. 2015 Nov;28(11):1492-503. doi: 10.1038/modpathol.2015.102. Epub 2015 Sep 18.

31.

Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.

Pérez-Gómez E, Andradas C, Blasco-Benito S, Caffarel MM, García-Taboada E, Villa-Morales M, Moreno E, Hamann S, Martín-Villar E, Flores JM, Wenners A, Alkatout I, Klapper W, Röcken C, Bronsert P, Stickeler E, Staebler A, Bauer M, Arnold N, Soriano J, Pérez-Martínez M, Megías D, Moreno-Bueno G, Ortega-Gutiérrez S, Artola M, Vázquez-Villa H, Quintanilla M, Fernández-Piqueras J, Canela EI, McCormick PJ, Guzmán M, Sánchez C.

J Natl Cancer Inst. 2015 Apr 8;107(6):djv077. doi: 10.1093/jnci/djv077. Print 2015 Jun.

32.

Loss of Snail2 favors skin tumor progression by promoting the recruitment of myeloid progenitors.

Villarejo A, Molina-Ortiz P, Montenegro Y, Moreno-Bueno G, Morales S, Santos V, Gridley T, Pérez-Moreno MA, Peinado H, Portillo F, Calés C, Cano A.

Carcinogenesis. 2015 May;36(5):585-97. doi: 10.1093/carcin/bgv021. Epub 2015 Mar 16.

33.

Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression.

Martin A, Salvador F, Moreno-Bueno G, Floristán A, Ruiz-Herguido C, Cuevas EP, Morales S, Santos V, Csiszar K, Dubus P, Haigh JJ, Bigas A, Portillo F, Cano A.

EMBO J. 2015 Apr 15;34(8):1090-109. doi: 10.15252/embj.201489975. Epub 2015 Mar 10.

34.

A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry.

Santacana M, Maiques O, Valls J, Gatius S, Abó AI, López-García MÁ, Mota A, Reventós J, Moreno-Bueno G, Palacios J, Bartosch C, Dolcet X, Matias-Guiu X.

Hum Pathol. 2014 Dec;45(12):2394-403. doi: 10.1016/j.humpath.2014.06.031. Epub 2014 Aug 23.

PMID:
25282036
35.

Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer.

Alonso-Alconada L, Muinelo-Romay L, Madissoo K, Diaz-Lopez A, Krakstad C, Trovik J, Wik E, Hapangama D, Coenegrachts L, Cano A, Gil-Moreno A, Chiva L, Cueva J, Vieito M, Ortega E, Mariscal J, Colas E, Castellvi J, Cusido M, Dolcet X, Nijman HW, Bosse T, Green JA, Romano A, Reventos J, Lopez-Lopez R, Salvesen HB, Amant F, Matias-Guiu X, Moreno-Bueno G, Abal M; ENITEC Consortium.

Mol Cancer. 2014 Sep 27;13:223. doi: 10.1186/1476-4598-13-223.

36.

Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer.

Alonso-Alconada L, Santacana M, Garcia-Sanz P, Muinelo-Romay L, Colas E, Mirantes C, Monge M, Cueva J, Oliva E, Soslow RA, Lopez MA, Palacios J, Prat J, Valls J, Krakstad C, Salvesen H, Gil-Moreno A, Lopez-Lopez R, Dolcet X, Moreno-Bueno G, Reventos J, Matias-Guiu X, Abal M.

Int J Cancer. 2015 Apr 15;136(8):1863-73. doi: 10.1002/ijc.29213. Epub 2014 Sep 29.

37.

Zeb1 and Snail1 engage miR-200f transcriptional and epigenetic regulation during EMT.

Díaz-López A, Díaz-Martín J, Moreno-Bueno G, Cuevas EP, Santos V, Olmeda D, Portillo F, Palacios J, Cano A.

Int J Cancer. 2015 Feb 15;136(4):E62-73. doi: 10.1002/ijc.29177. Epub 2014 Sep 12.

38.

EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination.

Gómez-Maldonado L, Tiana M, Roche O, Prado-Cabrero A, Jensen L, Fernandez-Barral A, Guijarro-Muñoz I, Favaro E, Moreno-Bueno G, Sanz L, Aragones J, Harris A, Volpert O, Jimenez B, del Peso L.

Oncogene. 2015 May 14;34(20):2609-20. doi: 10.1038/onc.2014.200. Epub 2014 Jul 14.

39.

Sin3b interacts with Myc and decreases Myc levels.

Garcia-Sanz P, Quintanilla A, Lafita MC, Moreno-Bueno G, García-Gutierrez L, Tabor V, Varela I, Shiio Y, Larsson LG, Portillo F, Leon J.

J Biol Chem. 2014 Aug 8;289(32):22221-36. doi: 10.1074/jbc.M113.538744. Epub 2014 Jun 20.

40.

Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives.

Díaz-López A, Moreno-Bueno G, Cano A.

Cancer Manag Res. 2014 Apr 25;6:205-16. doi: 10.2147/CMAR.S38156. eCollection 2014. Review.

41.

MicroRNAs as prognostic markers in ovarian cancer.

Llauradó M, Majem B, Altadill T, Lanau L, Castellví J, Sánchez-Iglesias JL, Cabrera S, De la Torre J, Díaz-Feijoo B, Pérez-Benavente A, Colás E, Olivan M, Doll A, Alameda F, Matias-Guiu X, Moreno-Bueno G, Carey MS, Del Campo JM, Gil-Moreno A, Reventós J, Rigau M.

Mol Cell Endocrinol. 2014 Jun 5;390(1-2):73-84. doi: 10.1016/j.mce.2014.03.006. Epub 2014 Apr 18. Review.

PMID:
24747602
42.

The Polycomb group protein RING1B is overexpressed in ductal breast carcinoma and is required to sustain FAK steady state levels in breast cancer epithelial cells.

Bosch A, Panoutsopoulou K, Corominas JM, Gimeno R, Moreno-Bueno G, Martín-Caballero J, Morales S, Lobato T, Martínez-Romero C, Farias EF, Mayol X, Cano A, Hernández-Muñoz I.

Oncotarget. 2014 Apr 30;5(8):2065-76.

43.

Gasdermin-B promotes invasion and metastasis in breast cancer cells.

Hergueta-Redondo M, Sarrió D, Molina-Crespo Á, Megias D, Mota A, Rojo-Sebastian A, García-Sanz P, Morales S, Abril S, Cano A, Peinado H, Moreno-Bueno G.

PLoS One. 2014 Mar 27;9(3):e90099. doi: 10.1371/journal.pone.0090099. eCollection 2014.

44.

Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization.

Canesin G, Cuevas EP, Santos V, López-Menéndez C, Moreno-Bueno G, Huang Y, Csiszar K, Portillo F, Peinado H, Lyden D, Cano A.

Oncogene. 2015 Feb 19;34(8):951-64. doi: 10.1038/onc.2014.23. Epub 2014 Mar 17.

PMID:
24632622
45.

MicroRNA-dependent regulation of transcription in non-small cell lung cancer.

Molina-Pinelo S, Gutiérrez G, Pastor MD, Hergueta M, Moreno-Bueno G, García-Carbonero R, Nogal A, Suárez R, Salinas A, Pozo-Rodríguez F, Lopez-Rios F, Agulló-Ortuño MT, Ferrer I, Perpiñá A, Palacios J, Carnero A, Paz-Ares L.

PLoS One. 2014 Mar 13;9(3):e90524. doi: 10.1371/journal.pone.0090524. eCollection 2014.

46.

LOXL2 catalytically inactive mutants mediate epithelial-to-mesenchymal transition.

Cuevas EP, Moreno-Bueno G, Canesin G, Santos V, Portillo F, Cano A.

Biol Open. 2014 Feb 15;3(2):129-37. doi: 10.1242/bio.20146841.

47.

A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition.

Díaz-Martín J, Díaz-López A, Moreno-Bueno G, Castilla MÁ, Rosa-Rosa JM, Cano A, Palacios J.

J Pathol. 2014 Feb;232(3):319-29. doi: 10.1002/path.4289.

PMID:
24122292
48.

ING4 regulates a secretory phenotype in primary fibroblasts with dual effects on cell proliferation and tumor growth.

Moreno A, Soleto I, García-Sanz P, Moreno-Bueno G, Palmero I.

Oncogene. 2014 Apr 10;33(15):1945-53. doi: 10.1038/onc.2013.145. Epub 2013 Apr 22.

PMID:
23604125
49.

E47 and Id1 interplay in epithelial-mesenchymal transition.

Cubillo E, Diaz-Lopez A, Cuevas EP, Moreno-Bueno G, Peinado H, Montes A, Santos V, Portillo F, Cano A.

PLoS One. 2013;8(3):e59948. doi: 10.1371/journal.pone.0059948. Epub 2013 Mar 26.

50.

Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1.

Ocaña OH, Córcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA.

Cancer Cell. 2012 Dec 11;22(6):709-24. doi: 10.1016/j.ccr.2012.10.012. Epub 2012 Nov 29.

Supplemental Content

Loading ...
Support Center